Integrated Microfluidic Systems for the Efficient Isolation of Circulating Leukemia Cells and Circulating Plasma Cells
Steve Soper, Foundation Distinguished Professor; Director, Center of BioModular Multi-scale System for Precision Medicine, Adjunct Professor, Ulsan National Institute of Science & Technology, The University of Kansas
Liquid biopsies are generating great interest within the biomedical
community due to the simplicity for securing important biomarkers to
manage complex diseases. We are developing a suite of microfluidic
devices that can process whole blood directly and engineered to
efficiently search for a variety of disease-associated liquid biopsy
markers and their subsequent molecular analysis. One microfluidic device
can isolate targets with recovery >90% and high purity (>80%) to
enable downstream analysis of the particular biomarker without requiring
single cell picking. We have also developed a microfluidic device for
imaging single cells. The aforementioned microfluidic devices can be
interfaced to a fluidic motherboard to allow for full process
automation, including cell selection from blood and then,
immunophenotyping and/or FISH of the isolated cells. In this
presentation, information will be shared on the operational parameters
of these devices for the selection of liquid biopsy markers, and the
downstream molecular information that can be garnered from the isolated
markers in acute myeloid / acute lymphoblastic leukemia (circulating
leukemia cells) and multiple myeloma (circulating plasma cells). The
attractive nature of using liquid biopsy markers for these two diseases
is that it circumvents the need for a patient to undergo a painful bone
marrow biopsy. Information will be provided as to the use of these
liquid biopsy markers to monitor relapse from minimum residual disease,
and stage patients for directing therapy.
|
|